Page 7 - ஆம்ஸ்டர்டாம் பல்கலைக்கழகம் மருத்துவ மையங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Feb 5, 2021 Volume, volume, volume may be the answer As findings from trial after trial provide evidence of the clinical benefit of SGLT2 inhibition in patients with reduced ejection fraction heart failure (HFrEF) DAPA-HF, EMPIRE-HF, EMPEROR-Reduced, there is little convincing left to do about the value of adding SGLT2 inhibitors to the HF armamentarium, as demonstrated by their inclusion in an updated expert decision pathway issued by the American College of Cardiology in early January 2021. But exactly why these drugs provide these demonstrable benefits is still debatable. Jesper Jensen, MD, PhD, of Herlev and Gentofte University Hospital, Herlev, Denmark, and University of Copenhagen, Copenhagen, Denmark, and colleagues drilled down into data from a prespecified substudy of EMPIRE-HF (EMPIRE-HF Renal) to investigate the “effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate (GFR) in patients with hear

Noord hollandHiddojl heerspinkPeggy peckJesper jensenTanabe pharmaEli lillyMarcel ha muskietMercksharp dohmeUniversity of copenhagenAmsterdam university medical centersAmerican college of cardiologyBoehringer ingelheimUniversity medical center groningenGentofte university hospital herlevEli lilly allianceGentofte university hospital